US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Monkeypox Concept

1,449.91

+26.251.84%

Number of Gainers:5

Number of Losers:6

Number of Flat:- -

PE:- -

High:1,453.52

Open:1,423.65

Low:1,416.12

Close:1,423.66

Loading ...

S&P 500 Falls 2%; Caterpillar Reports Downbeat Q1 Results

INOVIO to Present at Upcoming Scientific and Investor Conferences

Why Chimerix Inc. (CMRX) is Surging in 2025

Gilead Sciences to Present at Upcoming Investor Conferences

Gilead Sciences to Pay $202 Million in Settlement of Illegal Kickbacks Lawsuit

MT Newswires Live

U.S. Attorney in Manhattan Announces $202 Mln Settlement With Gilead Sciences for Using Speaker Programs to Pay Kickbacks to Doctors

THOMSON REUTERS

Gilead Sciences reaches $202 million settlement with US over kickbacks to doctors

Gilead Sciences (NasdaqGS:GILD) Showcases Promising Liver Disease Treatments At EASL Congress

Simply Wall St.

GeoVax Presents Gedeptin(R) Clinical Data at the American Association for Cancer Research Annual Meeting

3 Mid-Cap Stocks with Mounting Challenges

Gilead Sciences: AIDSVu Online Mapping Tool Helps Visualize HIV’s Impact in the United States

ACCESS Newswire

INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025

Labcorp beats quarterly profit estimate on diagnostic test demand

Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

Viatris Inc. (VTRS): Among Billionaire Ken Fisher’s Healthcare Stock Picks with Massive Upside Potential

Here's Why Siga Technologies Inc. (SIGA) Gained But Lagged the Market Today

BRIEF-Tonix Pharmaceuticals Holding Corp - Discontinued Enrollment And Terminated Phase 2 Catalyst Study - SEC Filing

BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EDT on 2025-04-25

Gilead Shares Down 3.6% After Quarterly Revenue Miss

THOMSON REUTERS

Viatris to Present at the BofA Securities 2025 Healthcare Conference

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4583/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4583","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","market":"US","secType":"PLATE","nameCN":"Monkeypox Concept","latestPrice":1449.9094,"timestamp":1746043199999,"preClose":1423.6627,"halted":0,"volume":26416433,"delay":0,"changeRate":0.018436,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":26.246704,"latestTime":"04-30 16:00:00 EDT","open":1423.6481,"high":1453.5166,"low":1416.1212,"amount":1425589469.076589,"amplitude":0.026267,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1746057600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.578278,"peRate":28.074483,"turnoverRate":0.009738,"increases":5,"decrements":6,"flats":0,"marketCap":163672603351,"floatMarketCap":163037168426},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","high":1453.5166,"amplitude":0.026267,"preClose":1423.6627,"low":1416.1212,"pbRate":"3.578278","latestPrice":1449.9094,"volume":26416433,"delay":0,"open":1423.6481,"prevYearClose":1284.7982,"prevWeekClose":1405.5511,"prevMonthClose":1502.9401,"prevQuarterClose":1502.9401,"fiveDayClose":1437.0104,"twentyDayClose":1493.5931,"sixtyDayClose":1346.2891,"secType":"PLATE","market":"US","turnoverRate":0.009738,"peRate":28.074483,"marketCap":163672603351,"floatMarketCap":163037168426,"timestamp":1746043199999,"nameCN":"Monkeypox Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4583\",,,,undefined,":{"bkCode":"BK4583","up":5,"down":6,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4583\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531231053","title":"S&P 500 Falls 2%; Caterpillar Reports Downbeat Q1 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2531231053","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531231053?lang=en_us&edition=fundamental","pubTime":"2025-04-30 21:52","pubTimestamp":1746021164,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/04/45100771/s-caterpillar-reports-downbeat-q1-results","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","BK4559","IVF","OEX","PSQ","BK4597","ESmain","TSYW.SI","BK4581","BK4149","LU0868494617.USD","IE0031619046.USD","UPRO","EJH","QID","JFBR","IVV","SPXU","BK4504","CAT","QLD","USAW.SI","BK4583","BK4532","BK4192","SDS","WNC","NQmain","LU2023250504.SGD","LU1974910355.USD","LU2237438978.USD","TQQQ","SH","LU2106854487.HKD","MNQmain","VOO","NVIW.SI",".SPX","USJW.SI","SSO","SQQQ","SPY","WGS","LU0868494708.USD","RGLS",".IXIC","BK4588","OEF","IE00B7SZL793.SGD"],"gpt_icon":1},{"id":"2531317950","title":"INOVIO to Present at Upcoming Scientific and Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2531317950","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531317950?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:05","pubTimestamp":1746014700,"startTime":"0","endTime":"0","summary":"PLYMOUTH MEETING, Pa., April 30, 2025 /PRNewswire/ --INOVIO , a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases,today announced that it will be presenting at several upcoming conferences, including a fireside chat at the Citizens JMP Life Sciences Conference in New York. INOVIO will also present for the first time data on the long-term clinical effect of lead candidate INO-3107 at the American Broncho-Esophagological Association  program at the Combined Otolaryngology Spring Meetings , the largest meeting of otolaryngologists in the U.S.European Laryngological Society Annual Congress Date: May 9Oral presentation: DNA immunotherapy, INO-3107, generates targeted immunologic response and results in surgery reduction for 81% of adults with recurrent respiratory papillomatosis in year 1. American Society of Gene and Cell Therapy Date: May 13Poster Abstract Session: Succe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/inovio-present-upcoming-scientific-investor-120500832.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inovio-present-upcoming-scientific-investor-120500832.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4175","INO","BK4139","COSM","BK4568","BK4583"],"gpt_icon":0},{"id":"2531087820","title":"Why Chimerix Inc. (CMRX) is Surging in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531087820","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531087820?lang=en_us&edition=fundamental","pubTime":"2025-04-30 17:46","pubTimestamp":1746006396,"startTime":"0","endTime":"0","summary":"We recently published a list of Why These 15 Healthcare Stocks Are Surging in 2025. In this article, we are going to take a look at where Chimerix Inc.  stands against other healthcare stocks that are surging in 2025.After lagging behind the broader market in 2024, many healthcare stocks are making a comeback this year. Healthcare spending has been continuously soaring and is projected to do so in the coming years due to demographic tailwinds. The industry now accounts for a fifth of the U.S. economy, and it’s a good idea to have exposure to it.Most executives now hold a favorable view of the industry’s prospects, a notable increase from 52% just a year ago. Moreover, it’s an industry that is more insulated from tariffs and macro risks.Of course, the top gainers here are not defensive healthcare stocks, but it’s still worth looking into the winners here if you are chasing potential multibaggers.Overall, CMRX ranks 8th on our list of healthcare stocks that are surging in 2025. While we ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-chimerix-inc-cmrx-surging-094636581.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SQQQ","USAW.SI","CMRX","USJW.SI",".IXIC","NQmain","PSQ","TQQQ","TSYW.SI","BK4583","NVIW.SI","MNQmain","QLD","QID"],"gpt_icon":1},{"id":"2531710023","title":"Gilead Sciences to Present at Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2531710023","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531710023?lang=en_us&edition=fundamental","pubTime":"2025-04-30 04:05","pubTimestamp":1745957100,"startTime":"0","endTime":"0","summary":"FOSTER CITY, Calif., April 29, 2025----Gilead Sciences, Inc.  announced today that its executives will be speaking at the following investor conferences:. BofA Securities Health Care Conference on Tuesday, May 13 at 11:20 AM Pacific Time. RBC Capital Markets Global Healthcare Conference on Wednesday, May 21 at 11:30 AM Eastern Time. Bernstein Annual Strategic Decisions Conference on Thursday, May 29 at 2:30 PM Eastern Time. Jefferies Global Healthcare Conference on Wednesday, June 4 at 11:05 AM Eastern Time. Goldman Sachs Annual Global Healthcare Conference on Tuesday, June 10 at 11:20 AM Eastern Time. Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gilead-sciences-present-upcoming-investor-200500133.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4583","BK4585","LU0889565916.HKD","LU1839511570.USD","LU0320765992.SGD","GILD","LU0109394709.USD","BK4568","IE00B3T34201.USD","LU1430594728.SGD","LU1571399168.USD","LU0058720904.USD","IE00B7SZLL34.SGD","LU0234570918.USD","BK4532","IE00BKVL7J92.USD","LU1066053197.SGD","LU2468319806.SGD","BK4578","IE00B19Z3B42.SGD","IE0002270589.USD","IE00BSNM7G36.USD","IE00BZ1G4Q59.USD","LU0289739699.SGD","IE00B19Z3581.USD","BK4550","LU2087621335.USD","LU2089984988.USD","BK4588","BK4139","LU1066051498.USD","LU1585245621.USD","BK4566"],"gpt_icon":0},{"id":"2531767764","title":"Gilead Sciences to Pay $202 Million in Settlement of Illegal Kickbacks Lawsuit","url":"https://stock-news.laohu8.com/highlight/detail?id=2531767764","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531767764?lang=en_us&edition=fundamental","pubTime":"2025-04-30 02:19","pubTimestamp":1745950748,"startTime":"0","endTime":"0","summary":"Gilead Sciences  has agreed to pay $202 million in the settlement of a civil fraud lawsuit accusing it of paying kickbacks to healthcare practitioners to promote its HIV treatment drugs, the US Attorney for the Southern District of New York said in a Tuesday statement.The illegal kickbacks caused false claims for Gilead's HIV drugs to be paid by federal healthcare programs, in violation of the False Claims Act, according to the statement.Under the settlement, Gilead agreed to pay a total sum of $202 million, of which around $176.9 million will be paid to the US and the remainder will be paid to various states.  As part of the settlement, the company also made extensive factual admissions regarding its conduct, the statement said.The settlement was approved Monday by US District Judge Paul Engelmayer.Gilead did not immediately reply to a request for comment from MT Newswires.Price: 106.17, Change: -0.17, Percent Change: -0.16","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B19Z3B42.SGD","LU0058720904.USD","LU0889565916.HKD","LU2468319806.SGD","IE00B7SZLL34.SGD","LU2087621335.USD","BK4585","LU0320765992.SGD","BK4578","GILD","BK4588","LU1585245621.USD","BK4566","LU1571399168.USD","BK4139","LU2089984988.USD","IE0002270589.USD","BK4532","LU0234570918.USD","BK4568","BK4583","IE00B19Z3581.USD","LU0109394709.USD","LU1839511570.USD","LU1066053197.SGD","LU1430594728.SGD","BK4550","IE00BZ1G4Q59.USD","LU1066051498.USD","IE00B3T34201.USD","IE00BKVL7J92.USD","LU0289739699.SGD","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"2531764556","title":"U.S. Attorney in Manhattan Announces $202 Mln Settlement With Gilead Sciences for Using Speaker Programs to Pay Kickbacks to Doctors","url":"https://stock-news.laohu8.com/highlight/detail?id=2531764556","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531764556?lang=en_us&edition=fundamental","pubTime":"2025-04-30 01:29","pubTimestamp":1745947786,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL1N3R7145:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0234570918.USD","LU2089984988.USD","LU0320765992.SGD","BK4532","LU0289739699.SGD","GILD","BK4583","LU1430594728.SGD","BK4568","LU0109394709.USD","LU1839511570.USD","LU1066051498.USD","LU2087621335.USD","IE00BZ1G4Q59.USD","LU0058720904.USD","IE0002270589.USD","IE00B3T34201.USD","IE00B7SZLL34.SGD","BK4578","LU1585245621.USD","BK4588","BK4566","IE00BSNM7G36.USD","LU1066053197.SGD","LU0889565916.HKD","LU1571399168.USD","IE00B19Z3581.USD","BK4139","BK4585","IE00BKVL7J92.USD","LU2468319806.SGD","IE00B19Z3B42.SGD","BK4550"],"gpt_icon":0},{"id":"2531764206","title":"Gilead Sciences reaches $202 million settlement with US over kickbacks to doctors","url":"https://stock-news.laohu8.com/highlight/detail?id=2531764206","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531764206?lang=en_us&edition=fundamental","pubTime":"2025-04-30 01:29","pubTimestamp":1745947786,"startTime":"0","endTime":"0","summary":"Gilead Sciences reaches $202 million settlement with US over kickbacks to doctorsNEW YORK, April 29 (Reuters) - Gilead Sciences GILD.O has reached a $202 million settlement to resolve a civil fraud la","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL1N3R7145:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0234570918.USD","LU1066051498.USD","LU2089984988.USD","BK4532","LU1839511570.USD","LU2087621335.USD","LU0058720904.USD","IE00B19Z3B42.SGD","IE0002270589.USD","LU1571399168.USD","LU1066053197.SGD","IE00B19Z3581.USD","BK4550","BK4583","IE00BKVL7J92.USD","LU0109394709.USD","LU0889565916.HKD","LU1585245621.USD","BK4578","LU1430594728.SGD","IE00B7SZLL34.SGD","LU0289739699.SGD","IE00BZ1G4Q59.USD","IE00BSNM7G36.USD","BK4566","IE00B3T34201.USD","BK4585","GILD","LU0320765992.SGD","BK4588","BK4568","LU2468319806.SGD"],"gpt_icon":0},{"id":"2531789793","title":"Gilead Sciences (NasdaqGS:GILD) Showcases Promising Liver Disease Treatments At EASL Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2531789793","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531789793?lang=en_us&edition=fundamental","pubTime":"2025-04-30 01:27","pubTimestamp":1745947636,"startTime":"0","endTime":"0","summary":"Gilead Sciences recently announced a presentation at the EASL Congress focusing on liver disease, with promising research in both hepatitis B and C. This comes alongside solid Q1 earnings results where a significant net income turnaround was noted. These developments, combined with a quarterly dividend declaration and ongoing share buybacks, potentially supported a 13% share price increase over the last quarter. Meanwhile, the general market showed strength with a 7% rise, suggesting Gilead's performance aligns with broader positive trends, further buoyed by robust earnings reports across various industries.We've identified 2 possible red flags with Gilead Sciences and understanding the impact should be part of your investment process.NasdaqGS:GILD Revenue & Expenses Breakdown as at Apr 2025. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gilead-sciences-nasdaqgs-gild-showcases-172716096.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4566","LU1571399168.USD","LU2087621335.USD","BK4585","LU1585245621.USD","BK4578","IE00B19Z3581.USD","LU0289739699.SGD","IE0002270589.USD","LU0058720904.USD","LU0234570918.USD","IE00BSNM7G36.USD","IE00B19Z3B42.SGD","IE00BZ1G4Q59.USD","GILD","BK4532","LU2089984988.USD","LU0109394709.USD","LU0889565916.HKD","BK4139","IE00B7SZLL34.SGD","BK4583","LU1430594728.SGD","LU1066051498.USD","BK4568","LU1066053197.SGD","LU1839511570.USD","BK4588","LU0320765992.SGD","LU2468319806.SGD","IE00BKVL7J92.USD","BK4550","IE00B3T34201.USD"],"gpt_icon":0},{"id":"2531765670","title":"GeoVax Presents Gedeptin(R) Clinical Data at the American Association for Cancer Research Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2531765670","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531765670?lang=en_us&edition=fundamental","pubTime":"2025-04-30 00:00","pubTimestamp":1745942400,"startTime":"0","endTime":"0","summary":"Advancing Gene-Directed Prodrug Therapy: Data Presented at AACR Supports Gedeptin's Potential in Solid Tumors. ATLANTA, GA - April 29, 2025  - GeoVax Labs, Inc. , a clinical-stage biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the presentation of new clinical data on its gene-directed enzyme prodrug therapy, Gedeptin, at the American Association for Cancer Research  Annual Meeting 2025, being held April 2530 in Chicago, IL.The presentation, titled \"Viral-Vectored, Gene-Directed Prodrug Therapy  in Needle-Accessible Solid Tumors,\" was delivered by J. Marc Pipas, M.D., Executive Medical Director, Oncology at GeoVax, during the Phase II Clinical Trials 1 Poster Session on April 29, 2025. The session drew significant interest from researchers and clinicians, underscoring the growing recognition of Gedeptin's therapeutic potential. The corresponding abstract was published in the AACR journal Cancer Research.\"These clini","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-presents-gedeptin-r-clinical-160000847.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2517655028.SGD","BK4195","BK4134","LU0107464264.USD","BK4117","BK4097","IT","LU2517655374.HKD","BK4232","SD","BK4139","AFG","LU2362540622.SGD","R","BK4211","LU2362541513.USD","LU0154245756.USD","LU0154245673.USD","BK4107","BK4213","BK4588","LU2362541273.HKD","GOVXW","LU2517655291.USD","BK4583","LU1814569148.SGD","GOVX","OS","PFS","BK4022","BK4585"],"gpt_icon":0},{"id":"2531675689","title":"3 Mid-Cap Stocks with Mounting Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2531675689","media":"StockStory","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531675689?lang=en_us&edition=fundamental","pubTime":"2025-04-29 21:04","pubTimestamp":1745931858,"startTime":"0","endTime":"0","summary":"Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.This is precisely where StockStory comes in - we do the heavy lifting to identify companies with solid fundamentals so you can invest with confidence. Keeping that in mind, here are three mid-cap stocks to swipe left on and some alternatives you should look into instead.Founded by Seattle-based entrepreneur Tom Gonser, DocuSign  is the pioneer of e-signature and offers software as a service that allows people and organisations to sign legally binding documents electronically.Average billings growth of 6.6% over the last year was subpar, suggesting it struggled to push its software and might have to lower prices to stimulate demand. Net revenue ret","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-mid-cap-stocks-mounting-130418701.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SJM","BK4023","BK4585","BK4613","DOCU","BK4567","BK4588","BK4528","DGX","BK4212","LU1854104046.USD","BK4583","BK4196","LU1854103824.USD"],"gpt_icon":0},{"id":"2531775351","title":"Gilead Sciences: AIDSVu Online Mapping Tool Helps Visualize HIV’s Impact in the United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2531775351","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531775351?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:35","pubTimestamp":1745930100,"startTime":"0","endTime":"0","summary":"NORTHAMPTON, MA / ACCESS Newswire / April 29, 2025 / Gilead is committed to using its virology expertise to advance HIV treatment and prevention to help end the epidemic. Since 2010, the company has partnered with Emory University in Atlanta to launch AIDSVu - an online mapping tool that visualizes granular data related to the HIV epidemic in the United States.The tool was designed to help increase awareness and understanding of the impact of HIV across the U.S., especially in the South.AIDSVu analyses have revealed that although new HIV diagnoses have been declining throughout the country from 2008 to 2022, this progress has been uneven across regions. For example, the U.S. South saw only a 17% decrease in new HIV diagnoses during this period compared to a 43% decrease in the Northeast.\"Data is power,\" he says. \"Whether you are a mathematical person or a visual person, you can come and look and we can have a common understanding of what the HIV epidemic looks like in our city, in our ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gilead-sciences-aidsvu-online-mapping-123500779.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1066051498.USD","BK4583","LU1571399168.USD","LU0234570918.USD","IE00B19Z3581.USD","LU0058720904.USD","BK4211","LU2087621335.USD","IE0002270589.USD","IE00B3T34201.USD","BK4139","UBCP","IE00BKVL7J92.USD","LU0109394709.USD","BK4568","IE00B19Z3B42.SGD","BK4550","BK4578","LU0289739699.SGD","IE00B7SZLL34.SGD","BK4585","GILD","IE00BSNM7G36.USD","BK4532","BK4566","LU0889565916.HKD","LU1430594728.SGD","LU1585245621.USD","LU1066053197.SGD","LU0320765992.SGD","LU1839511570.USD","LU2089984988.USD","IE00BZ1G4Q59.USD","LU2468319806.SGD","BK4588"],"gpt_icon":0},{"id":"2531733506","title":"INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531733506","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531733506?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:05","pubTimestamp":1745928300,"startTime":"0","endTime":"0","summary":"PLYMOUTH MEETING, Pa., April 29, 2025 /PRNewswire/ -- INOVIO , a biotechnology company focused on developing and commercializing DNA medicines tohelp treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that first quarter 2025 financial results will be released after the market close on May 13, 2025. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update.INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancers, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/inovio-report-first-quarter-2025-120500615.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inovio-report-first-quarter-2025-120500615.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4568","INO","BK4139","BK4583"],"gpt_icon":0},{"id":"2531783789","title":"Labcorp beats quarterly profit estimate on diagnostic test demand","url":"https://stock-news.laohu8.com/highlight/detail?id=2531783789","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531783789?lang=en_us&edition=fundamental","pubTime":"2025-04-29 18:53","pubTimestamp":1745924011,"startTime":"0","endTime":"0","summary":"Labcorp beats quarterly profit estimate on diagnostic test demandApril 29 (Reuters) - Laboratory operator Labcorp LH.N beat analysts' estimate for first-quarter profit on Tuesday, helped by robust dem","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL4N3R70W1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0742534661.SGD","LU0048573561.USD","LU0251131958.USD","BK4585","LU0251142724.SGD","BK4567","LH","BK4588","LU1059921491.USD","LU0006061336.USD","DGX","BK4550","LU1854104046.USD","BK4583","BK4196","LU1854103824.USD"],"gpt_icon":0},{"id":"2531608266","title":"Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2531608266","media":"Business Wire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531608266?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:05","pubTimestamp":1745870700,"startTime":"0","endTime":"0","summary":"SAN DIEGO, April 28, 2025----Contineum Therapeutics, Inc.  , a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology  indications, today announced the appointment of Timothy Watkins, M.D., M.Sc., to the Company’s executive team as its Chief Medical Officer and Head of Development. Effective immediately, Dr. Watkins will lead all clinical development and medical affairs activities at Contineum. Dr. Watkins succeeds Stephen L. Huhn, M.D., who has been the Company’s Chief Medical Officer since early 2020. Dr. Huhn will serve as an advisor during the leadership transition.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/contineum-therapeutics-appoints-timothy-watkins-200500814.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0234570918.USD","BK4139","BK4007","IE00BSNM7G36.USD","LU0289739699.SGD","SQQQ","BK4568","LU1839511570.USD","LU1585245621.USD",".IXIC","IE00B19Z3B42.SGD","IE0002270589.USD","BK4588","IE00B19Z3581.USD","LU0058720904.USD","TQQQ","IE00B7SZLL34.SGD","BK4550","IE00B3T34201.USD","QID","BK4585","USAW.SI","BK4566","LU0889565916.HKD","NVIW.SI","USJW.SI","BK4532","CTNM","BK4578","GILD","BK4583","QLD","MNQmain","LU1066051498.USD","TSYW.SI","LU0109394709.USD","LU1066053197.SGD","LENZ","IE00BZ1G4Q59.USD","LU1430594728.SGD","LU2087621335.USD","LU1571399168.USD","LU2468319806.SGD","IE00BKVL7J92.USD","PSQ","LU0320765992.SGD","NQmain","LU2089984988.USD"],"gpt_icon":1},{"id":"2530468800","title":"Viatris Inc. (VTRS): Among Billionaire Ken Fisher’s Healthcare Stock Picks with Massive Upside Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2530468800","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530468800?lang=en_us&edition=fundamental","pubTime":"2025-04-28 03:06","pubTimestamp":1745780763,"startTime":"0","endTime":"0","summary":"We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential. In this article, we are going to take a look at where Viatris Inc.  stands against other Billionaire Ken Fisher’s healthcare stock picks with massive upside potential.The healthcare industry, an essential component of global well-being and economic resilience, is undergoing significant changes. The industry, which is thought to account for more than 10% of the world’s GDP, is set to enter a new era characterized by demographic shifts, digital innovation, and regulatory realignment. Stakeholders in the life sciences, diagnostics, and healthcare services ecosystem face a conundrum as of 2025: stability is threatened by ongoing financial strain, growing operational complexity, and geopolitical risks, despite the abundance of growth opportunities.Meanwhile, recent geopolitical developments are casting a shadow on global healthcare supply networks. In April 2025, President Donal","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/viatris-inc-vtrs-among-billionaire-190603648.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PSQ","HCSG","TQQQ","BK4585","BK4007","QID","MNQmain","VTRS","LU1839511570.USD","QLD","BK4583","LU2087621335.USD","NQmain","USJW.SI","USAW.SI","NVIW.SI","BK4137","BK4588","SQQQ","TSYW.SI",".IXIC"],"gpt_icon":1},{"id":"2530194205","title":"Here's Why Siga Technologies Inc. (SIGA) Gained But Lagged the Market Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2530194205","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530194205?lang=en_us&edition=fundamental","pubTime":"2025-04-26 05:45","pubTimestamp":1745617517,"startTime":"0","endTime":"0","summary":"In the latest trading session, Siga Technologies Inc.  closed at $6.51, marking a +0.39% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.74%. Elsewhere, the Dow gained 0.05%, while the tech-heavy Nasdaq added 1.26%.The company's stock has climbed by 16.34% in the past month, exceeding the Medical sector's loss of 7.7% and the S&P 500's loss of 4.77%.The investment community will be paying close attention to the earnings performance of Siga Technologies Inc. in its upcoming release.It's also important for investors to be aware of any recent modifications to analyst estimates for Siga Technologies Inc. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.In terms of valuation, Siga Technologies Inc. is currently trading at a Forward P/E ratio of 49.85. For comparison, its industry has an average Forw","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-siga-technologies-inc-214517292.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4583","SIGA"],"gpt_icon":0},{"id":"2530193844","title":"BRIEF-Tonix Pharmaceuticals Holding Corp - Discontinued Enrollment And Terminated Phase 2 Catalyst Study - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2530193844","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530193844?lang=en_us&edition=fundamental","pubTime":"2025-04-26 05:03","pubTimestamp":1745614995,"startTime":"0","endTime":"0","summary":"BRIEF-Tonix Pharmaceuticals Holding Corp - Discontinued Enrollment And Terminated Phase 2 Catalyst Study - SEC FilingApril 25  - Tonix Pharmaceuticals Holding Corp TNXP.O:TONIX PHARMACEUTICALS HOLDING CORP - DISCONTINUED ENROLLMENT AND TERMINATED PHASE 2 CATALYST STUDY - SEC FILINGTONIX PHARMACEUTICALS - EVALUATING NEW STUDY DESIGNS AND NEW ENDPOINTS FOR FURTHER DEVELOPMENT OF TNX-1300Source text: [ID:n0001999371-25-004807]Further company coverage: TNXP.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nFWN3R32K1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TNXP","BK4139","BK4583"],"gpt_icon":1},{"id":"2530678153","title":"BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EDT on 2025-04-25","url":"https://stock-news.laohu8.com/highlight/detail?id=2530678153","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530678153?lang=en_us&edition=fundamental","pubTime":"2025-04-25 23:01","pubTimestamp":1745593264,"startTime":"0","endTime":"0","summary":"BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EDT on 2025-04-25Nasdaq 100 .NDXTop PerformersPercent ChangeCharter Communications Inc CHTR.OQ+9.9%Tesla Inc TSLA.OQ+6%Microstrategy Inc MSTR.OQ+4.0%GE Healthcare Technologies Inc GEHC.OQ+3.0%Alphabet Inc GOOGL.OQ+2.1%Bottom PerformersPercent ChangeT-Mobile US Inc TMUS.OQ-10.5%Intel Corp INTC.OQ-6.4%Old Dominion Freight Line Inc ODFL.OQ-5.8%Gilead Sciences Inc GILD.OQ-3.6%MongoDB Inc MDB.OQ-2.3%The Nasdaq 100 .NDX lost 0.89 points, or 0.00%, to 19,213.51 and recorded 2 new highs and one new low. 38 stocks rose and 63 fell as declining issues outnumbered advancers by about a 1.7-to-1 ratio.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nL8N3R31VK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","LU2271345857.HKD","LU2471134952.CNY","LU1119994496.HKD","STRK","LU2602419157.SGD","LU2430703178.SGD","LU1670628061.USD","LU0302445910.USD","GILD","LU2063271972.USD","BK4515","CHTR","SG9999014906.USD","LU2065169927.USD","LU2023251221.USD","TSLA","LU2191332357.HKD","LU0345774631.USD","LU2250418816.HKD","LU2361044949.HKD","LU0170899867.USD","LU1303367103.USD","IE00BJLML261.HKD","LU0348723411.USD","LU0127658192.USD","LU0077335932.USD","LU2468319806.SGD","LU1551013342.USD","LU1121112475.USD","ODFL","LU2272731782.SGD","TSYW.SI","BK4538","MSTR","LU0251131958.USD","GEHC","INTC","LU0426417589.USD","LU1674673428.USD","MDB","BK4534","GOOGL","LU2028103732.USD","TMUS","LU1629891620.HKD","LU0215105999.USD","LU0080751232.USD","LU1585245621.USD"],"gpt_icon":1},{"id":"2530136072","title":"Gilead Shares Down 3.6% After Quarterly Revenue Miss","url":"https://stock-news.laohu8.com/highlight/detail?id=2530136072","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530136072?lang=en_us&edition=fundamental","pubTime":"2025-04-25 21:32","pubTimestamp":1745587936,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nL4N3R31CJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE0002270589.USD","LU0109394709.USD","IE00B19Z3B42.SGD","LU1066053197.SGD","BK4583","IE00B7SZLL34.SGD","LU2468319806.SGD","BK4585","BK4139","BK4550","IE00BSNM7G36.USD","LU0058720904.USD","BK4588","LU0289739699.SGD","LU1571399168.USD","LU2087621335.USD","BK4566","BK4568","LU1430594728.SGD","LU1585245621.USD","LU2089984988.USD","IE00BKVL7J92.USD","LU0320765992.SGD","BK4578","IE00B19Z3581.USD","GILD","LU0234570918.USD","LU1066051498.USD","IE00BZ1G4Q59.USD","BK4532","LU0889565916.HKD","LU1839511570.USD","IE00B3T34201.USD"],"gpt_icon":0},{"id":"2530933185","title":"Viatris to Present at the BofA Securities 2025 Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2530933185","media":"PR Newswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530933185?lang=en_us&edition=fundamental","pubTime":"2025-04-25 18:59","pubTimestamp":1745578740,"startTime":"0","endTime":"0","summary":"PITTSBURGH, April 25, 2025 /PRNewswire/ -- Viatris Inc. , a global healthcare company, will present at the BofA Securities 2025 Healthcare Conference in Las Vegas, NV, on Tuesday, May 13, 2025. The company's presentation will begin at 5 p.m. PT / 8 p.m. ET.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/viatris-present-bofa-securities-2025-105900711.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/viatris-present-bofa-securities-2025-105900711.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4137","BK4588","LU1839511570.USD","VTRS","LU2087621335.USD","HCSG","BK4007","BK4583"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":73,"code":"91000000","status":"200"}]}}